iBio(IBIO) - 2026 Q2 - Quarterly Results

Exhibit 99.1 · Closed a $26 million private placement financing led by Frazier Life Sciences, announced on January 9th. The net proceeds from the raise are intended for the advancement of key preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, as well as general corporate purposes. With this funding the Company's cash runway now extends into third quarter of fiscal year 2028. · Presented new non-human primate (NHP) data on IBIO-610, a pote ...